Title : Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.

Pub. Date : 2003

PMID : 14687441






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Rivastigmine acetylcholinesterase (Cartwright blood group) Homo sapiens
2 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Rivastigmine acetylcholinesterase (Cartwright blood group) Homo sapiens
3 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Rivastigmine acetylcholinesterase (Cartwright blood group) Homo sapiens